Faricimab (Vabysmo) is a bispecific antibody drug targeting vascular endothelial growth factor (VEGF) and angiopoietin-2 (Ang-2). Developed by Genentech, it is indicated for the treatment of neovascular age-related macular degeneration (nAMD), diabetic macular edema (DME), and macular edema secondary to retinal vein occlusion (RVO).
How to Purchase Faricimab (Vabysmo)
Overseas Purchase
Patients may choose to consult and purchase the drug at hospital pharmacies or authorized pharmacies in countries/regions where Faricimab has been launched.
Since drug prices may be affected by factors such as regional differences and exchange rate fluctuations, patients need to make a budget and plan in advance before purchasing.
Purchase Through Medical Service Institutions
Patients may consult domestic overseas medical service institutions that cooperate with international pharmacies or pharmaceutical companies.
These institutions usually provide legal import channels and can offer professional consultation and guidance.
Precautions for Purchasing Faricimab (Vabysmo)
Verification of Medical Institution Qualifications
Possess professional diagnosis and treatment qualifications for retinal diseases.
Be equipped with first-aid equipment and medications for managing complications related to intravitreal injection.
Have professional pharmacists responsible for drug receipt, storage, and preparation.
Physicians have received special training on this drug.
Inspection of Package Integrity
The outer box clearly displays the "VABYSMO®" trademark and the active ingredient name "faricimab-svoa".
Indicates the specification "6 mg (0.05 mL of 120 mg/mL solution)".
Includes a complete National Drug Code (NDC).
Bears the "Rx only" (prescription-only medication) label.
Identifies the manufacturer "Genentech, Inc." and the U.S. License No. "U.S. License No. 1048".
Methods to Identify Authentic Faricimab (Vabysmo)
Anti-Counterfeiting Features of the Package
Uses special-material packaging boxes and unique printing processes.
Includes a distinct 2D barcode area.
The prefilled syringe package contains a 30-gauge × ½-inch injection filter needle.
The vial package contains an 18-gauge × 1½-inch sterile blunt transfer filter needle.
Identification of Drug Characteristics
The solution appears clear to opalescent and colorless to tan.
Each syringe/vial contains 6 mg of the active ingredient in a volume of 0.05 mL.
No visible particles or precipitates are present.
The pH value is 5.5 after reconstitution (if applicable; note: prefilled syringes are ready-to-use and do not require reconstitution).
Prefilled syringes have a unique dose marking (0.05 mL dose indicator).
